Arderlyx (NASDAQ:ARDX) And Kyowa Kirin Present Data Supporting Efficacy and Safety Of Tenapanor At ASN

Arderlyx Inc. (NASDAQ:ARDX) and Kyowa Kirin Co. Ltd have highlighted new clinical data that was presented within five posters during this year’s American Society of Nephrology meeting at Kidney Week 2020.

Ardelyx and Kyowa presents data on tenapanor at ASN

Among the posters presented three highlighted tenapanor clinical data from the company’s Phase 3 trials in the US, including AMPLIFY, BLOCK, and PHREEDOME studies. The other two presented data from phase 2 trials evaluating the safety and efficacy of tenapanor on hemodialysis patients in Japan. Kyowa Kirin conducted studies in Japan for treating cardiorenal diseases.

Ardelyx has licensed exclusive rights to Kyowa Kirin for the development and commercialization of tenapanor in Japan. Kyowa Kirin conducted three phases 2 studies in Japan of tenapanor as KHK7791. Ardelyx discovered and developed tenapanor as a first in class treatment to control serum phosphorus in adult patients with chronic kidney disease and are on dialysis. The therapy is currently under FDA reviews for possible marketing approval.

Tenapanor showing potential in the management of hyperphosphatemia

Professor Kevin Martin, the Internal Medicine and Nephrology Division director at Saint Louis University, said that over the last 30 years, there has been little progress in attaining sustained hyperphosphatemia control. This is regardless of the consequences of elevated phosphorous levels and the development of various phosphate binders. Despite treatment with phosphate binders, hyperphosphatemia 77% of patients in dialysis are unable to maintain phosphorous levels.

However, recent advances in mechanistic understanding of phosphate absorption have resulted in a new way of thing regarding hyperphosphatemia management. Martin added that tenapanor’s proprietary action mechanism targeting paracellular phosphate transport and clinical data has continued to support its safety and efficacy as a potential therapy for hyperphosphatemia.

Besides the poster presentations made during the ASN annual meeting, an Exhibitor Spotlight presentation was sponsored by the company. The presentation offers insight into advances in the science of phosphate absorption as well as clinical data on tenapanor. The sponsored presentation was titled: “ADVANCING THE SCIENCE OF PHOSPHATE ABSORPTION: Paracellular Pathway and Implications for Phosphorus Management.”